Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.
Identifieur interne : 001D64 ( PubMed/Corpus ); précédent : 001D63; suivant : 001D65Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.
Auteurs : Mary C. Hu ; Taff Jones ; Richard T. Kenney ; Dale L. Barnard ; David S. Burt ; George H. LowellSource :
- Vaccine [ 0264-410X ] ; 2007.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (biosynthesis), Cysteine Endopeptidases (administration & dosage), Cysteine Endopeptidases (immunology), Cytokines (biosynthesis), Drug Combinations, Female, Immunization, Lipopolysaccharides (administration & dosage), Lipopolysaccharides (immunology), Lung (immunology), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, SARS Virus (immunology), Spike Glycoprotein, Coronavirus, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Cysteine Endopeptidases, Lipopolysaccharides, Vaccines, Synthetic, Viral Vaccines.
- chemical , biosynthesis : Antibodies, Viral, Cytokines.
- chemical , immunology : Cysteine Endopeptidases, Lipopolysaccharides, Membrane Glycoproteins, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- immunology : Lung, SARS Virus.
- Administration, Intranasal, Animals, Drug Combinations, Female, Immunization, Mice, Mice, Inbred BALB C, Spike Glycoprotein, Coronavirus.
Abstract
The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.
DOI: 10.1016/j.vaccine.2007.06.017
PubMed: 17640780
Links to Exploration step
pubmed:17640780Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.</title><author><name sortKey="Hu, Mary C" sort="Hu, Mary C" uniqKey="Hu M" first="Mary C" last="Hu">Mary C. Hu</name><affiliation><nlm:affiliation>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway, Bothell, WA 98011, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, Taff" sort="Jones, Taff" uniqKey="Jones T" first="Taff" last="Jones">Taff Jones</name></author><author><name sortKey="Kenney, Richard T" sort="Kenney, Richard T" uniqKey="Kenney R" first="Richard T" last="Kenney">Richard T. Kenney</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author><author><name sortKey="Burt, David S" sort="Burt, David S" uniqKey="Burt D" first="David S" last="Burt">David S. Burt</name></author><author><name sortKey="Lowell, George H" sort="Lowell, George H" uniqKey="Lowell G" first="George H" last="Lowell">George H. Lowell</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17640780</idno><idno type="pmid">17640780</idno><idno type="doi">10.1016/j.vaccine.2007.06.017</idno><idno type="wicri:Area/PubMed/Corpus">001D64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.</title><author><name sortKey="Hu, Mary C" sort="Hu, Mary C" uniqKey="Hu M" first="Mary C" last="Hu">Mary C. Hu</name><affiliation><nlm:affiliation>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway, Bothell, WA 98011, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, Taff" sort="Jones, Taff" uniqKey="Jones T" first="Taff" last="Jones">Taff Jones</name></author><author><name sortKey="Kenney, Richard T" sort="Kenney, Richard T" uniqKey="Kenney R" first="Richard T" last="Kenney">Richard T. Kenney</name></author><author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name></author><author><name sortKey="Burt, David S" sort="Burt, David S" uniqKey="Burt D" first="David S" last="Burt">David S. Burt</name></author><author><name sortKey="Lowell, George H" sort="Lowell, George H" uniqKey="Lowell G" first="George H" last="Lowell">George H. Lowell</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (biosynthesis)</term><term>Cysteine Endopeptidases (administration & dosage)</term><term>Cysteine Endopeptidases (immunology)</term><term>Cytokines (biosynthesis)</term><term>Drug Combinations</term><term>Female</term><term>Immunization</term><term>Lipopolysaccharides (administration & dosage)</term><term>Lipopolysaccharides (immunology)</term><term>Lung (immunology)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>SARS Virus (immunology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Lipopolysaccharides</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Lipopolysaccharides</term><term>Membrane Glycoproteins</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Drug Combinations</term><term>Female</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Spike Glycoprotein, Coronavirus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17640780</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>34</Issue><PubDate><Year>2007</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.</ArticleTitle><Pagination><MedlinePgn>6334-40</MedlinePgn></Pagination><Abstract><AbstractText>The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Mary C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway, Bothell, WA 98011, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Taff</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kenney</LastName><ForeName>Richard T</ForeName><Initials>RT</Initials></Author><Author ValidYN="Y"><LastName>Barnard</LastName><ForeName>Dale L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Burt</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Lowell</LastName><ForeName>George H</ForeName><Initials>GH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01AI15435</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC1 AI062600</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AI-15435</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1-UC1-AI062600-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493785">Protollin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17640780</ArticleId><ArticleId IdType="pii">S0264-410X(07)00695-0</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2007.06.017</ArticleId><ArticleId IdType="pmc">PMC7115497</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2006 Apr 24;24(17):3624-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16497416</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Aug 15;23(35):4385-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16005746</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 Jan 30;24(5):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2004 Sep 9;22(27-28):3691-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15315848</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(9):5833-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15827197</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2001 Oct 12;20(1-2):218-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11567767</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Immun. 1995 Jun;63(6):2382-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7768627</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Exp Biol Med (Maywood). 2003 Jul;228(7):866-73</Citation><ArticleIdList><ArticleId IdType="pubmed">12876307</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Jul;11(7):1016-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16022774</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 Mar 6;24(10):1625-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16243411</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Semin Immunol. 2005 Oct;17(5):378-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15996480</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Jan 4;23(7):924-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Oct 10;23(42):4959-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15993989</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Immun. 2001 Jul;69(7):4545-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11401998</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001D64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17640780
|texte= Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17640780" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |